Heparin-induced thrombocytopenia, unspecified
ICD-10 D75.829 is a billable code used to indicate a diagnosis of heparin-induced thrombocytopenia, unspecified.
Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated adverse reaction to heparin, characterized by a decrease in platelet count and an increased risk of thrombosis. HIT typically occurs 5 to 14 days after exposure to heparin, although it can occur sooner in patients with prior exposure. The condition is caused by the formation of antibodies against complexes of heparin and platelet factor 4 (PF4), leading to platelet activation and aggregation. This results in thrombocytopenia, which can be severe, and paradoxically, an increased risk of thrombotic events, including venous thromboembolism and arterial thrombosis. Diagnosis is primarily clinical, supported by laboratory tests that detect HIT antibodies. Management involves immediate cessation of heparin and the use of alternative anticoagulants. The unspecified designation indicates that the specific type or severity of HIT is not documented, which may complicate treatment decisions and coding accuracy.
Detailed clinical notes on platelet counts, symptoms, and treatment plans.
Patients presenting with thrombocytopenia after heparin exposure.
Ensure clear documentation of the timeline of heparin exposure and platelet count monitoring.
Comprehensive patient history and physical examination findings.
Management of patients with HIT in the context of other comorbidities.
Document any alternative anticoagulants used and their indications.
Used to monitor platelet levels in patients suspected of HIT.
Document the reason for the CBC and the results.
Hematologists may require more frequent monitoring.
HIT is primarily caused by the formation of antibodies against heparin-PF4 complexes, leading to platelet activation and a paradoxical increase in thrombotic events.
